微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 84.44% | 0.49% | -1.56% | 15/158 | -2.04% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 85.78% | -0.16% | -0.61% | 13/158 | 14.94% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 86.31% | 1.68% | 2.96% | 6/158 | 32.08% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 83.83% | -2.98% | -0.24% | 15/158 | 51.81% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 84.04% | -2.3% | -2.19% | 12/158 | 22.66% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 85.92% | -0.33% | 1.22% | 11/158 | 33.21% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 84.89% | -1.13% | -1.76% | 10/158 | 51.68% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 86.41% | 9.98% | 0.46% | 10/158 | 51.58% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 86.02% | 7.55% | -0.22% | 10/158 | 32.59% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 86.21% | 7.69% | 0.41% | 9/158 | 38.52% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 85.86% | 7.61% | 9.28% | 13/158 | 52.97% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 78.57% | 14.04% | -1.76% | 24/158 | 53.83% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 79.98% | 15.77% | -0.1% | 21/158 | 6.03% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 80.06% | 13.28% | 0.33% | 24/158 | 21.28% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 79.79% | 12.98% | 15.81% | 23/158 | 54.44% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 68.9% | 13.23% | -0.28% | 47/158 | 55.28% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 69.09% | 4.3% | -2.25% | 36/158 | 46.93% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 70.67% | 4.79% | 0.07% | 36/158 | 47.39% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 70.63% | 2.3% | 16.07% | 30/158 | 54.24% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 60.85% | 2.87% | -8.14% | 59/158 | -147.15% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 66.24% | 7.95% | -1.79% | 38/158 | 56.61% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 67.45% | 8.78% | -2.3% | 37/158 | 54.34% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 69.04% | 20.51% | 16.71% | 28/158 | 55.43% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 59.15% | -1.94% | -3.6% | 63/158 | -1232.32% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 61.36% | -6.26% | -1.03% | 43/158 | 55.43% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 62% | -10.62% | 8.22% | 45/158 | 55.42% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 57.29% | -21.9% | -5.02% | 46/158 | 51.19% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 60.32% | -10.86% | -7.85% | 51/158 | -209.94% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 65.46% | -5.18% | -5.64% | 27/158 | 54.16% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 69.36% | 1.22% | -5.44% | 22/158 | 53.57% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 73.35% | 5.22% | 8.41% | 15/158 | 54.1% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 67.66% | 11.93% | -1.98% | 29/158 | 52.58% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 69.03% | 11.7% | 0.73% | 19/158 | 49.3% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 68.53% | 9.11% | -1.7% | 18/158 | 48.06% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 69.71% | 6% | 15.32% | 16/158 | 46.94% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 60.45% | -2.96% | -2.18% | 31/158 | 48.52% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 61.8% | -2.66% | -1.61% | 21/158 | 46.19% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 62.81% | -3.63% | -4.49% | 23/158 | 46.26% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 65.77% | -2.63% | 5.57% | 13/158 | 43.86% | 贝达药业 | 97.01% | 行业排名> |